Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service dialysis access cases in Arkansas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (245 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 32 | 2,313 | 29% |
| 2020 | 32 | 2,107 | 32% |
| 2021 | 25 | 1,629 |
AV fistula and graft creation, access circuit angioplasty and stenting. Professional codes (what the surgeon bills): CPT 36821, 36830, 36902, 36903, 36905, 36906, 36818, 36819.
Since 2021 dialysis (ESRD) patients may join Medicare Advantage, and they have moved to it far faster than the county average, so fee-for-service decline here overstates the real one even after adjustment.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 95% of the cases CMS names in Arkansas; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral arterial intervention | 23 | 2,979−1.4%/yr | −1.4%/yr | 7.61.2× | 45% | 2,520 in 2030−2.8%/yr |
| Superficial venous ablation |
Dialysis access in every state, and its device makers · Every procedure market in Arkansas · Every state · Compare with Texas
| ≈ 1,150 |
| – |
| 2026 est. | ≈ 1,150 | – |
| 37% |
| 2022 | 19 | 1,450 | 40% |
| 2023 | 20 | 1,314 | 46% |
| 2024 | 13 | 1,246 | 49% |
| 2025 from claims | – | 1,149 1,055–1,216 | 50% |
| 2026 forecast | – | 1,150 1,012–1,328 | 51% |
| 2027 forecast | – | 1,152 985–1,373 | 51% |
| 2028 forecast | – | 1,153 962–1,412 | 52% |
| 2029 forecast | – | 1,154 942–1,447 | 53% |
| 2030 forecast | – | 1,154 925–1,479 | 53% |
In 2025, 38% hospital outpatient, 60% surgery center, 2% office. The share outside the hospital has moved +16 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Surgery center |
|---|---|---|
| 2026 · ~1,200 | ~430 | ~720 |
| 2027 · ~1,200 | ~420 | ~730 |
| 2028 · ~1,200 | ~420 | ~740 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 64% (60% in 2025), office about 0% (2% in 2025), hospital outpatient about 36% (38% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| −15%/yr |
| 5.0 |
| 68% |
| 10,100 in 2030−1%/yr |
| Georgia | 74 | 6,490−18%/yr | −18%/yr | 7.8 | 72% | 6,500 in 20300%/yr |
| Virginia | 50 | 5,185−16%/yr | −16%/yr | 5.1 | 61% | 5,340 in 2030+0.5%/yr |
| North Carolina | 55 | 5,158−18%/yr | −18%/yr | 5.4 | 66% | 4,610 in 2030−1.9%/yr |
| Maryland | 40 | 4,421−11%/yr | −11%/yr | 5.1 | 64% | 4,640 in 2030+0.8%/yr |
| South Carolina | 30 | 3,370−11%/yr | −11%/yr | 5.1 | 29% | 3,610 in 2030+1.2%/yr |
| Tennessee | 37 | 2,923−15%/yr | −15%/yr | 4.3 | 53% | 3,040 in 2030+0.7%/yr |
| Alabama | 35 | 2,267−19%/yr | −19%/yr | 5.4 | 57% | 2,000 in 2030−2.1%/yr |
| Louisiana | 35 | 2,265−18%/yr | −18%/yr | 5.8 | 26% | 2,030 in 2030−1.8%/yr |
| Mississippi | 17 | 1,861−18%/yr | −18%/yr | 5.1 | 36% | 1,780 in 2030−0.7%/yr |
| Kentucky | 25 | 1,806−14%/yr | −14%/yr | 4.1 | 13% | 1,510 in 2030−3%/yr |
| Oklahoma | 31 | 1,548−12%/yr | −12%/yr | 3.3 | 12% | 1,570 in 2030+0.3%/yr |
| Delaware | 7 | 781−12%/yr | −12%/yr | 4.7 | 89% | 780 in 20300%/yr |
| District of Columbia | 3 | 402−12%/yr | −12%/yr | 6.6 | 82% | 350 in 2030−2.1%/yr |
| West Virginia | 2 | 305−22%/yr | −22%/yr | 1.5 | 0% | 350 in 2030+2.3%/yr |
| 11 |
| 666−14%/yr |
| −14%/yr |
| 1.70.3× |
| 78% |
| 580 in 2030−2.1%/yr |
| Thrombectomy, IVC filters & venous stents | 6 | 614+8.4%/yr | +8.4%/yr | 1.60.9× | 5% | 680 in 2030+1.8%/yr |
| Carotid revascularization | 13 | 532−8.8%/yr | −8.8%/yr | 1.41.1× | 0% | 550 in 2030+0.4%/yr |
| Aortic endografts (EVAR/TEVAR) | 6 | 201−3.4%/yr | −3.4%/yr | 0.51.1× | 0% | 170 in 2030−3.1%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
W L Gore & Associates leads with 59% of company spending on these surgeons in 2025, +53 pts on 2024.
In 2025, 5 companies reported engagement with Arkansas’s surgeons worth $590 in consulting, speaking, meals and travel tied to these products, about $45 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 1 clearance or approval in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.